Axim Biotechnologies Seeks FDA CLIA Waiver for Lactoferrin Diagnostic Test

Axim Biotechnologies Seeks FDA CLIA Waiver for Lactoferrin Diagnostic Test

Axim Biotechnologies, Inc. has taken a significant step towards broadening the accessibility of its Lactoferrin diagnostic test by filing a Pre-Submission with the U.S. Food and Drug Administration (FDA) for a Clinical Laboratory Improvement Amendments (CLIA) Waiver. This move is aimed at facilitating the diagnosis and monitoring of Aqueous Deficient Dry Eye Disease (ADDE) by enabling the test’s administration in non-laboratory settings. The Tea…

Axim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test

Open the article to view the coverage from NewMediaWire